产品名称 |
Calu-6人退行性癌细胞 |
货号 |
ZQ0382 |
产品介绍 |
Calu-6细胞系是一种人类非小细胞肺癌(NSCLC)细胞系,来源于一位61岁白人女性患者的胸腔积液。该细胞系建立于1975年,一直是肺癌研究的关键模型。Calu-6细胞具有独特的上皮形态,被广泛用于研究肺癌的生物学,包括转移机制、耐药性和肿瘤微环境。这些细胞尤其以其在异种移植模型中形成肿瘤的能力而闻名,这使得它们对肿瘤生长和治疗反应的体内研究具有很高的价值。 |
种属 |
人 |
性别/年龄 |
女/61岁 |
组织 |
退行性癌 |
疾病 |
未分化癌,肺腺癌 |
细胞类型 |
肿瘤细胞 |
形态学 |
上皮 |
生长方式 |
贴壁 |
倍增时间 |
大约26~72小时 |
培养基和添加剂 |
MEM(品牌:中乔新舟 货号:ZQ-300)+10%FBS(品牌:中乔新舟 货号:ZQ500-A)+1%P/S(中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
|
生物安全等级 |
BSL-1 |
STR位点信息 |
Amelogenin: X CSF1PO: 12 D5S818: 11 D13S317: 11 D7S820: 10 D16S539: 13 vWA: 17 TH01: 9 TPOX: 8 |
培养条件 |
95%空气,5%二氧化碳;37℃ |
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
ATCC; HTB-56 DSMZ; ACC-734 |
供应限制 |
仅供科研使用 |
货号 |
ZQ0382 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)
PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)
PubMed=6148444; DOI=10.1093/jnci/73.4.801
Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H. Jr., Mitchell J.B.
Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.
J. Natl. Cancer Inst. 73:801-807(1984)
PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)
PubMed=3940644
Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
Cancer Res. 46:798-806(1986)
PubMed=3129183
Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R.
Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas.
Cancer Res. 48:2674-2677(1988)
PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)
PubMed=2388294; DOI=10.1093/jnci/82.17.1420
McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.
Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.
J. Natl. Cancer Inst. 82:1420-1426(1990)
PubMed=1855224
Lehman T.A., Bennett W.P., Metcalf R.A., Welsh J.A., Ecker J., Modali R.V., Ullrich S., Romano J.W., Appella E., Testa J.R., Gerwin B.I., Harris C.C.
p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Cancer Res. 51:4090-4096(1991)
PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x
Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R.
Alterations of integrin expression in human lung cancer.
Jpn. J. Cancer Res. 84:168-174(1993)
PubMed=7972006; DOI=10.1073/pnas.91.23.11045
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)
PubMed=7834619
Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T., Takahashi T., Takahashi T.
In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
Cancer Res. 55:514-517(1995)
PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)
PubMed=12794755; DOI=10.1002/ijc.11184
Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T.
RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
Int. J. Cancer 106:45-51(2003)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20679594; DOI=10.1093/jnci/djq279
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)
产品名称 | 价格 | 指令 |
支原体检测试剂盒 | ¥800.00 | 购物车 》 |
支原体清除试剂盒 | ¥600.00 | 购物车 》 |
国产转染试剂 | ¥800.00 | 购物车 》 |
慢病毒介导基因沉默或过表达 | ¥询价 | 购物车 》 |
荧光素酶标记 | ¥询价 | 购物车 》 |
绿/红色荧光蛋白标记 | ¥询价 | 购物车 》 |
MEM(含有NEAA)基础培养基 | ¥56.00 | 购物车 》 |
EMEM(含有NEAA)完全培养基 | ¥350.00 | 购物车 》 |
优级胎牛血清 | ¥2580(开学促销) | 购物车 》 |
双抗(青霉素/链霉素)溶液 | ¥384.00 | 购物车 》 |
支原体抑制剂 10 mg/ml; 1 ml(定制) | ¥1808.00 | 购物车 》 |
人源细胞STR鉴定服务 | ¥900.00 | 购物车 》 |